Ligand Pharmaceuticals (LGND) Q2 results: Revenues: $25M (-72.2%); Royalties: $6.6M (-79.0%); Material sales: $8.5M (+11.8%); License fees, milestones and other revenues: $9.8M (-80.8%).
Net Loss: ($14.4M) (-119.7%); Loss Per Share: ($0.74) (-124.7%); Non-GAAP Net Income: $13.9M (-77.1%); Non-GAAP EPS: $0.68 (-73.7%).
2019 guidance: Total Revenues: ~$118M (unch); non-GAAP EPS: ~$3.20 (unch).
Previously: Ligand Pharmaceuticals EPS beats by $0.02, beats on revenue(July 30)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.